<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinform Adv</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinform Adv</journal-id>
    <journal-id journal-id-type="publisher-id">bioadv</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics Advances</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2635-0041</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9998102</article-id>
    <article-id pub-id-type="doi">10.1093/bioadv/vbad018</article-id>
    <article-id pub-id-type="publisher-id">vbad018</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Application Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genetics and Population Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>LAVAA: a lightweight association viewer across ailments</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9739-0249</contrib-id>
        <name>
          <surname>Fauman</surname>
          <given-names>Eric B</given-names>
        </name>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/conceptualization" degree-contribution="lead">Conceptualization</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="http://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Validation" vocab-term-identifier="http://credit.niso.org/contributor-roles/validation" degree-contribution="equal">Validation</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="lead">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – review &amp; editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="lead">Writing – review &amp; editing</role>
        <aff><institution>Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical</institution>, Cambridge, MA 02139, <country country="US">USA</country></aff>
        <xref rid="vbad018-cor1" ref-type="corresp"/>
        <!--eric.fauman@pfizer.com-->
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Keppo</surname>
          <given-names>Stella</given-names>
        </name>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Software" vocab-term-identifier="http://credit.niso.org/contributor-roles/software" degree-contribution="lead">Software</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/visualization" degree-contribution="lead">Visualization</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="supporting">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – review &amp; editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing – review &amp; editing</role>
        <aff><institution>Visual Communication Design, Aalto University</institution>, Espoo 02150, <country country="FI">Finland</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Cerioli</surname>
          <given-names>Nicola</given-names>
        </name>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="http://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Software" vocab-term-identifier="http://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="http://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/visualization" degree-contribution="equal">Visualization</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="supporting">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – review &amp; editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing – review &amp; editing</role>
        <aff><institution>Visual Communication Design, Aalto University</institution>, Espoo 02150, <country country="FI">Finland</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Vyas</surname>
          <given-names>Rupesh</given-names>
        </name>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="http://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Software" vocab-term-identifier="http://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/visualization" degree-contribution="lead">Visualization</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – review &amp; editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing – review &amp; editing</role>
        <aff><institution>Visual Communication Design, Aalto University</institution>, Espoo 02150, <country country="FI">Finland</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kurki</surname>
          <given-names>Mitja</given-names>
        </name>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Software" vocab-term-identifier="http://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="supporting">Writing – original draft</role>
        <aff><institution>Finnish Institute for Molecular Medicine (FIMM), University of Helsinki</institution>, Helsinki 00014, <country country="FI">Finland</country></aff>
        <aff><institution>Program for Medical and Population Genetics, Broad Institute of MIT and Harvard</institution>, Cambridge, MA 02142, <country country="US">USA</country></aff>
        <aff><institution>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard</institution>, Cambridge, MA 02142, <country country="US">USA</country></aff>
        <aff><institution>Analytic and Translational Genetics Unit, Massachusetts General Hospital</institution>, Boston, MA 02114, <country country="US">USA</country></aff>
        <aff><institution>Center for Genomic Medicine, Massachusetts General Hospital</institution>, Boston, MA 02114, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Daly</surname>
          <given-names>Mark</given-names>
        </name>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="http://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="lead">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="http://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="http://credit.niso.org/contributor-roles/project-administration" degree-contribution="supporting">Project administration</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Resources" vocab-term-identifier="http://credit.niso.org/contributor-roles/resources" degree-contribution="equal">Resources</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="supporting">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – review &amp; editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing – review &amp; editing</role>
        <aff><institution>Finnish Institute for Molecular Medicine (FIMM), University of Helsinki</institution>, Helsinki 00014, <country country="FI">Finland</country></aff>
        <aff><institution>Program for Medical and Population Genetics, Broad Institute of MIT and Harvard</institution>, Cambridge, MA 02142, <country country="US">USA</country></aff>
        <aff><institution>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard</institution>, Cambridge, MA 02142, <country country="US">USA</country></aff>
        <aff><institution>Analytic and Translational Genetics Unit, Massachusetts General Hospital</institution>, Boston, MA 02114, <country country="US">USA</country></aff>
        <aff><institution>Center for Genomic Medicine, Massachusetts General Hospital</institution>, Boston, MA 02114, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Reeve</surname>
          <given-names>Mary Pat</given-names>
        </name>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="http://credit.niso.org/contributor-roles/data-curation" degree-contribution="equal">Data curation</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="http://credit.niso.org/contributor-roles/project-administration" degree-contribution="lead">Project administration</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="http://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="supporting">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="http://credit.niso.org" vocab-term="Writing – review &amp; editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing – review &amp; editing</role>
        <aff><institution>Finnish Institute for Molecular Medicine (FIMM), University of Helsinki</institution>, Helsinki 00014, <country country="FI">Finland</country></aff>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Forslund</surname>
          <given-names>Sofia</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="vbad018-cor1">To whom correspondence should be addressed. <email>eric.fauman@pfizer.com</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-02-15">
      <day>15</day>
      <month>2</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>15</day>
      <month>2</month>
      <year>2023</year>
    </pub-date>
    <volume>3</volume>
    <issue>1</issue>
    <elocation-id>vbad018</elocation-id>
    <history>
      <date date-type="received">
        <day>12</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>06</day>
        <month>2</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>08</day>
        <month>2</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>11</day>
        <month>2</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>09</day>
        <month>3</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="vbad018.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Biobank scale genetic associations results over thousands of traits can be difficult to visualize and navigate.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We have created LAVAA, a visualization web-application to generate genetic volcano plots for simultaneously considering the <italic toggle="yes">P</italic>-value, effect size, case counts, trait class and fine-mapping posterior probability at a single-nucleotide polymorphism (SNP) across a range of traits from a large set of genome-wide association study. We find that user interaction with association results in LAVAA can enrich and enhance the biological interpretation of individual loci.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>LAVAA is available as a stand-alone web service (<ext-link xlink:href="https://geneviz.aalto.fi/LAVAA/" ext-link-type="uri">https://geneviz.aalto.fi/LAVAA/</ext-link>) and will be available in future releases of the finngen.fi website starting with release 10 in late 2023.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Business Finland</institution>
            <institution-id institution-id-type="DOI">10.13039/501100014438</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>HUS 4685/31/2016</award-id>
        <award-id>UH 4386/31/2016</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="5"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>The genome-wide association study (GWAS) has been a very successful technique for elucidating the role of inherited variation in human biology and pathophysiology. The importance of a statistical association between a genetic variant and a trait of interest is conveyed by the strength of the association, reflected in the <italic toggle="yes">P</italic>-value, and the magnitude of the association, reflected in the effect size. The Manhattan plot and the regional association plot are two popular methods to explore the distribution of the <italic toggle="yes">P</italic>-values across the genome for one trait at a time (<xref rid="vbad018-B1" ref-type="bibr">Boughton <italic toggle="yes">et al.</italic>, 2021</xref>). However, even when interpreting the results of a single GWAS at a single locus it is essential to consider that result in the context of all other genetic studies. The so-called ‘phenome-wide association scan’ or PheWAS, can be presented in a manner analogous to the Manhattan plot, showing the distribution of <italic toggle="yes">P</italic>-values across a set of traits, but now at a single variant at a time (<xref rid="vbad018-B3" ref-type="bibr">Denny <italic toggle="yes">et al.</italic>, 2010</xref>).</p>
    <p>As cohort sizes grow, however, it is becoming increasingly important to consider effect size in addition to the <italic toggle="yes">P</italic>-value. Indeed, in the limit we might expect that eventually all genes in relevant tissues will show statistical significance with all traits (<xref rid="vbad018-B2" ref-type="bibr">Boyle <italic toggle="yes">et al.</italic>, 2017</xref>). Thus it is likely the case that the most important biological impact of a locus is revealed not in the trait with the strongest <italic toggle="yes">P</italic>-value but the one with the largest effect.</p>
    <p>For continuous traits (e.g. biomarker levels) at a single-nucleotide polymorphism (SNP) the trait with the strongest <italic toggle="yes">P</italic>-value will typically be the trait with the largest effect size (given a fixed sample size, cohort, and standard error across traits) (<xref rid="vbad018-F1" ref-type="fig">Fig. 1</xref>) (<xref rid="vbad018-B10" ref-type="bibr">Sham and Purcell, 2014</xref>). However, this will not be the case for dichotomous traits (e.g. ‘disease’ vs ‘not-disease’), where the number of ‘cases’ can vary widely across the traits, even if the total number of subjects is constant (<xref rid="vbad018-F2" ref-type="fig">Fig. 2</xref>).</p>
    <fig position="float" id="vbad018-F1">
      <label>Fig. 1.</label>
      <caption>
        <p>Sample LAVAA plot for a continuous trait on imported data. This LAVAA plot was created using data imported from OpenGWAS (<ext-link xlink:href="https://gwas.mrcieu.ac.uk/" ext-link-type="uri">https://gwas.mrcieu.ac.uk/</ext-link>) (<xref rid="vbad018-B5" ref-type="bibr">Hemani <italic toggle="yes">et al.</italic>, 2018</xref>) representing metabolomics traits at the <italic toggle="yes">GCKR</italic> locus (rs1260326) from UK Biobank (<xref rid="vbad018-B8" ref-type="bibr">Richardson <italic toggle="yes">et al.</italic>, 2022</xref>; <xref rid="vbad018-B11" ref-type="bibr">Sudlow <italic toggle="yes">et al.</italic>, 2015</xref>). Each dot represents the –log10(<italic toggle="yes">P</italic>-value) and beta value for one metabolite trait. The colors represent the classes of measured traits</p>
      </caption>
      <graphic xlink:href="vbad018f1" position="float"/>
    </fig>
    <fig position="float" id="vbad018-F2">
      <label>Fig. 2.</label>
      <caption>
        <p>Sample LAVAA plot for a set of dichotomous traits. Since effective sample size varies drastically from trait to trait the –log10(<italic toggle="yes">P</italic>-value) and effect size are no longer coupled. This figure represents disease traits from release 7 of FinnGen at the same SNP referenced in <xref rid="vbad018-F1" ref-type="fig">Fig. 1</xref>. Colors represent groups of related diseases</p>
      </caption>
      <graphic xlink:href="vbad018f2" position="float"/>
    </fig>
    <p>The genomic context of the association of a single SNP in a GWAS is also important. Because of linkage disequilibrium, the <italic toggle="yes">P</italic>-value for a trait at a particular SNP can reach genome-wide significance (<italic toggle="yes">P</italic> &lt; 5 × 10<sup>−8</sup>) but may be entirely explained by a much stronger signal 10 s or 100 s of kilobases away. Statistical fine-mapping techniques (<xref rid="vbad018-B12" ref-type="bibr">Wang <italic toggle="yes">et al.</italic>, 2020</xref>) can pinpoint likely causal variants among correlated variants, but this information is typically absent from visualizations or analyses at a specific SNP.</p>
    <p>FinnGen is one of the largest nationwide biobank studies, now encompassing 309 154 subjects with genetic results across 3095 dichotomous traits (as of release 7) (<ext-link xlink:href="https://r7.finngen.fi/" ext-link-type="uri">https://r7.finngen.fi/</ext-link>) (<xref rid="vbad018-B6" ref-type="bibr">Locke <italic toggle="yes">et al.</italic>, 2019</xref>). To assist researchers with extracting valuable genetic, biological and medical insights from this wealth of data we have designed and implemented LAVAA, a lightweight association viewer across ailments.</p>
  </sec>
  <sec>
    <title>2 Methods</title>
    <p>LAVAA was developed using the D3 JavaScript library. D3 provides a flexible framework and an active online community to accelerate development of new applications. We also included the following libraries: d3-tip, d3-legend and d3-format. These libraries further streamline development by adding components created specifically for use by D3-based applications. We also included the simplebar library to support an intuitive user interface design.</p>
    <p>The LAVAA user interface is designed to support two aspects of the research process: analysis and display of results. Following ‘Shneiderman’s Mantra’ (<xref rid="vbad018-B9" ref-type="bibr">Schneiderman, 1996</xref>) LAVAA first provides an overview of the data with a volcano plot with options to then zoom and retrieve specific details on demand. The initial plot provides the following four dimensions: (i) the magnitude of the association (the beta or the natural log of the odds ratio) on the <italic toggle="yes">x</italic>-axis; (ii) the strength of the association (the –log10 of the <italic toggle="yes">P</italic>-value from the logistic or linear regression) on the <italic toggle="yes">y</italic>-axis; (iii) the case count displayed as the diameter of the halo around each dot; and (iv) the category of each trait conveyed by the color of the halo around each dot. In this way, every association for a particular variant can be viewed and explored (<xref rid="vbad018-F2" ref-type="fig">Fig. 2</xref>).</p>
    <p>LAVAA provides multiple mechanisms for the user to further explore the data. If fine-mapping results are available, traits which have been fine-mapped to the current variant can be highlighted with a dark circle around the central dot. Mousing over any dot displays the association statistics and provides an option to label the dot with those details. A user can zoom in to just the genome-wide significant results (–log10(<italic toggle="yes">P</italic>) &gt; 7.3) or can sweep and select an arbitrary region of the display. The latter action generates a small table of the association results for all selected variants.</p>
    <p>Because the thousands of traits in FinnGen have been mapped to a smaller number of specific categories we implemented a convex hull function which draws the user’s eye toward sets of related phenotypes (<xref rid="vbad018-F3" ref-type="fig">Fig. 3</xref>). A convex hull is defined as the smallest polygon which contains a specific set of points. By changing the focus to categories rather than individual phenotypes the convex hull provides the user with a more global view and reduces the cognitive load (<xref rid="vbad018-B13" ref-type="bibr">Xu and Chun, 2007</xref>).</p>
    <fig position="float" id="vbad018-F3">
      <label>Fig. 3.</label>
      <caption>
        <p>Example LAVAA plot demonstrating the use of convex hulls to group related traits. This is showing only the significant associations from <xref rid="vbad018-F2" ref-type="fig">Figure 2</xref>. The convex hull for ‘endocrine, nutritional and metabolic diseases’ crosses the beta = 0 line because the allele at rs1260326 which increases risk for type 2 diabetes also decreases risk for mixed hyperlipidemia</p>
      </caption>
      <graphic xlink:href="vbad018f3" position="float"/>
    </fig>
    <sec>
      <title>2.1 Interactive plots of user-provided data</title>
      <p>Users can generate their own LAVAA plots by downloading the TSV summary of association results from any variant page in the finngen.fi website (e.g. <ext-link xlink:href="https://r5.finngen.fi/variant/2-27508073-T-C" ext-link-type="uri">https://r5.finngen.fi/variant/2-27508073-T-C</ext-link>). This TSV can be directly uploaded to the LAVAA tool here: <ext-link xlink:href="https://geneviz.aalto.fi/LAVAA/" ext-link-type="uri">https://geneviz.aalto.fi/LAVAA/</ext-link>. The LAVAA visualization tool is integrated into the finngen.fi website as of release 10, due to be available to the general public by the end of 2023.</p>
      <p>Currently, all users can use the standalone LAVAA tool and can also download or fork the LAVAA project on GitHub, here: <ext-link xlink:href="https://github.com/FINNGEN/volcano_plot" ext-link-type="uri">https://github.com/FINNGEN/volcano_plot</ext-link>.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <p>We demonstrate the utility of LAVAA plot with an example from the FinnGen. FinnGen employs a rich variety of case-control definitions, refining or expanding the number of subjects included. For example, the broadest definition of ‘Endocrine, nutritional and metabolic diseases’ encompasses over 118 000 cases out of 309 154 subjects. This broad category shows no significant association at the well-known <italic toggle="yes">GCKR</italic> non-synonymous variant, rs1260326 (<italic toggle="yes">P</italic> = 0.074, beta = 0.01 in FinnGen r7). However, as the LAVAA plot reveals, more specific definitions of this disease category can have much stronger associations (<xref rid="vbad018-F2" ref-type="fig">Fig. 2</xref>). The largest effect size for a genome-wide significant association at rs1260326 is for ‘mixed hyperlipidemia’ with only 849 cases but with an effect size of −0.32 and a <italic toggle="yes">P</italic>-value of 8 × 10<sup>−11</sup>. Similarly, the LAVAA plot illustrates the bifurcation of lipid and diabetic traits with the diabetes risk allele being associated with lower lipid levels and reduced use of statins (<xref rid="vbad018-F2" ref-type="fig">Figs 2</xref> and <xref rid="vbad018-F3" ref-type="fig">3</xref>).</p>
  </sec>
  <sec>
    <title>4 Conclusion</title>
    <p>LAVAA is a novel web-based visualization tool for assorted traits at a particular locus. By simultaneously representing multiple features per association, LAVAA permits researchers to more deeply explore biobank-scale genetic results such as from FinnGen.</p>
  </sec>
</body>
<back>
  <sec>
    <title>Author contributions</title>
    <p>Eric B. Fauman (Conceptualization [lead], Supervision [equal], Validation [equal], Writing—original draft [lead], Writing—review &amp; editing [lead]), Stella Keppo (Software [lead], Visualization [lead], Writing—original draft [supporting], Writing—review &amp; editing [supporting]), Nicola Cerioli (Methodology [equal], Software [equal], Supervision [equal], Visualization [equal], Writing—original draft [supporting], Writing—review &amp; editing [supporting]), Rupesh Vyas (Methodology [equal], Software [equal], Visualization [lead], Writing—review &amp; editing [supporting]), Mitja Kurki (Software [equal], Writing—original draft [supporting]), Mark Daly (Funding acquisition [lead], Methodology [supporting], Project administration [supporting], Resources [equal], Writing—original draft [supporting], Writing—review &amp; editing [supporting]), and Mary Pat Reeve (Data curation [equal], Project administration [lead], Supervision [equal], Writing—original draft [supporting], Writing—review &amp; editing [supporting])</p>
  </sec>
  <sec>
    <title>Ethics statement</title>
    <p>Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017.</p>
    <p>The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/14.02/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata THL/2364/14.02/2020 and Statistics Finland [permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20)].</p>
    <p>The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 7 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154 and amendment #1 (August 17 2020), Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 §/2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 &amp; 06.10.2020), Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb, Genentech Inc., Merck Sharp &amp; Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc. and Novartis Pharma AG. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (<ext-link xlink:href="https://www.auria.fi/biopankki" ext-link-type="uri">www.auria.fi/biopankki</ext-link>), THL Biobank (<ext-link xlink:href="https://www.thl.fi/biobank" ext-link-type="uri">www.thl.fi/biobank</ext-link>), Helsinki Biobank (<ext-link xlink:href="https://www.helsinginbiopankki.fi" ext-link-type="uri">www.helsinginbiopankki.fi</ext-link>), Biobank Borealis of Northern Finland (<ext-link xlink:href="https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx" ext-link-type="uri">https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx</ext-link>), Finnish Clinical Biobank Tampere (<ext-link xlink:href="https://www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere" ext-link-type="uri">www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere</ext-link>), Biobank of Eastern Finland (<ext-link xlink:href="https://www.ita-suomenbiopankki.fi/en" ext-link-type="uri">www.ita-suomenbiopankki.fi/en</ext-link>), Central Finland Biobank (<ext-link xlink:href="https://www.ksshp.fi/fi-FI/Potilaalle/Biopankki" ext-link-type="uri">www.ksshp.fi/fi-FI/Potilaalle/Biopankki</ext-link>), Finnish Red Cross Blood Service Biobank (<ext-link xlink:href="https://www.veripalvelu.fi/verenluovutus/biopankkitoiminta" ext-link-type="uri">www.veripalvelu.fi/verenluovutus/biopankkitoiminta</ext-link>) and Terveystalo Biobank (<ext-link xlink:href="https://www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/" ext-link-type="uri">www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/</ext-link>). All Finnish Biobanks are members of BBMRI.fi infrastructure (<ext-link xlink:href="https://www.bbmri.fi" ext-link-type="uri">www.bbmri.fi</ext-link>) and FINBB biobank cooperative (<ext-link xlink:href="https://finbb.fi/" ext-link-type="uri">https://finbb.fi/</ext-link>) is the coordinator of the BBMRI-ERIC operations in Finland covering all Finnish biobanks.</p>
    <p><italic toggle="yes">Conflict of Interest</italic>: E.B.F. is an employee of and shareholder in Pfizer, Inc.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>The data shown in Figures 1, 2, and 3 of this article are available for download from the stand-alone LAVAA server at <ext-link xlink:href="https://geneviz.aalto.fi/LAVAA/" ext-link-type="uri">https://geneviz.aalto.fi/LAVAA/</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="vbad018-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boughton</surname><given-names>A.P.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>LocusZoom.js: interactive and embeddable visualization of genetic association study results</article-title>. <source>Bioinformatics</source>, <volume>37</volume>, <fpage>3017</fpage>–<lpage>3018</lpage>.<pub-id pub-id-type="pmid">33734315</pub-id></mixed-citation>
    </ref>
    <ref id="vbad018-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyle</surname><given-names>E.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>An expanded view of complex traits: from polygenic to omnigenic</article-title>. <source>Cell</source>, <volume>169</volume>, <fpage>1177</fpage>–<lpage>1186</lpage>.<pub-id pub-id-type="pmid">28622505</pub-id></mixed-citation>
    </ref>
    <ref id="vbad018-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Denny</surname><given-names>J.C.</given-names></string-name></person-group><etal>et al</etal> (<year>2010</year>) <article-title>PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations</article-title>. <source>Bioinformatics</source>, <volume>26</volume>, <fpage>1205</fpage>–<lpage>1210</lpage>.<pub-id pub-id-type="pmid">20335276</pub-id></mixed-citation>
    </ref>
    <ref id="vbad018-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hemani</surname><given-names>G.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>The MR-Base platform supports systematic causal inference across the human phenome</article-title>. <source>eLife</source>, <volume>7</volume>, <fpage>e34408</fpage>.<pub-id pub-id-type="pmid">29846171</pub-id></mixed-citation>
    </ref>
    <ref id="vbad018-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Locke</surname><given-names>A.E.</given-names></string-name></person-group><etal>et al</etal>; <collab>FinnGen Project</collab>. (<year>2019</year>) <article-title>Exome sequencing of Finnish isolates enhances rare-variant association power</article-title>. <source>Nature</source>, <volume>572</volume>, <fpage>323</fpage>–<lpage>328</lpage>.<pub-id pub-id-type="pmid">31367044</pub-id></mixed-citation>
    </ref>
    <ref id="vbad018-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richardson</surname><given-names>T.G.</given-names></string-name></person-group><etal>et al</etal> (<year>2022</year>) <article-title>Characterising metabolomic signatures of lipid-modifying therapies through drug target Mendelian randomisation</article-title>. <source>PLoS Biol</source>., <volume>20</volume>, <fpage>e3001547</fpage>.<pub-id pub-id-type="pmid">35213538</pub-id></mixed-citation>
    </ref>
    <ref id="vbad018-B9">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Schneiderman</surname><given-names>B.</given-names></string-name></person-group> (<year>1996</year>) The eyes have it: a task by data type taxonomy for information visualizations. In: Proceedings 1996 IEEE Symposium on Visual Languages, Boulder, CO, USA, pp. <fpage>336</fpage>–<lpage>343</lpage>.</mixed-citation>
    </ref>
    <ref id="vbad018-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sham</surname><given-names>P.C.</given-names></string-name>, <string-name><surname>Purcell</surname><given-names>S.M.</given-names></string-name></person-group> (<year>2014</year>) <article-title>Statistical power and significance testing in large-scale genetic studies</article-title>. <source>Nat. Rev. Genet</source>., <volume>15</volume>, <fpage>335</fpage>–<lpage>346</lpage>.<pub-id pub-id-type="pmid">24739678</pub-id></mixed-citation>
    </ref>
    <ref id="vbad018-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sudlow</surname><given-names>C.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) <article-title>UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of Middle and old age</article-title>. <source>PLoS Med</source>., <volume>12</volume>, <fpage>e1001779</fpage>.<pub-id pub-id-type="pmid">25826379</pub-id></mixed-citation>
    </ref>
    <ref id="vbad018-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>G.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>A simple new approach to variable selection in regression, with application to genetic fine mapping</article-title>. <source>J. R Stat. Soc. B</source>, <volume>82</volume>, <fpage>1273</fpage>–<lpage>1300</lpage>.</mixed-citation>
    </ref>
    <ref id="vbad018-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chun</surname><given-names>M.M.</given-names></string-name></person-group> (<year>2007</year>) <article-title>Visual grouping in human parietal cortex</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>104</volume>, <fpage>18766</fpage>–<lpage>18771</lpage>.<pub-id pub-id-type="pmid">17998539</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
